Fibrin Monomer in Chronic HCV ‎Cirrhotic Patients

Abstract

Background: Cirrhosis is a diffuse pathophysiological state of the liver that is thought to be the final stage of various liver injuries. It is characterized by chronic necroinflammatory and fibrogenetic processes, which result in the conversion of normal liver architecture into structurally abnormal nodules, dense fibrotic septa, concomitant parenchymal exaustment, and liver tissue collapse. Aim of this Work is to study fibrin monomer in chronic HCV patients with and without portal hypertension aiming to investigate its value in these patients and if it aides in early detection of thrombus formation.‎ Patients and Methods: They were fifty chronic HCV cirrhotic patients with and ‎without portal hypertension. Patients of these study were selected from Tropical and internal medicine departments and investigated at Clinical Pathology department in Tanta University hospitals, Faculty of Medicine, Tanta University during the period from July 2018 to January 2020. Results: The individuals included in this study were comprised as: Group 1: Twenty-five healthy volunteers (matched for age and gender) were investigated as a control group. Group 2: Twenty-five diagnosed cirrhotic patients without portal hypertension. Group 3: Twenty-five diagnosed cirrhotic patients with portal hypertension. The result of the present study was statistically analyzed, summarized and presented in tables. Conclusion: It may be concluded that soluble fibrin monomer complex could represent a useful marker ‎for early detection of thrombus generation in chronic HCV cirrhotic patients. It may enable ‎us to pick up vulnerable patients in early stages to start early management.